207/Pn/2026 - Delivery of the Medicinal Product Tender - 145113935

Procurement Summary

Country: Poland

Summary: 207/Pn/2026 - Delivery of the Medicinal Product Brexucabtagene Autoleucel - Annual Demand for Drug Programs: B.12.Fm "Treatment of Patients with B-Cell Lymphoma" and B.65 "Treatment of Patients With....

Deadline: 13 Aug 2026

Posting Date: 14 Jul 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 145113935

Document Ref. No.: 486553-2026

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: Refer Document

CPV Classification

33600000 - Pharmaceutical products

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_detailsLogin to see details

Tender Details

207/PN/2026 - Delivery of the medicinal product Brexucabtagene autoleucel - annual demand for drug programs: B.12.FM "Treatment of patients with B-cell lymphoma" and B.65 "Treatment of patients with.... 207/PN/2026 - Delivery of a medicinal product Brexucabtagene autoleucel - annual requirement for drug programs: B.12.FM "Treatment of patients with B-cell lymphoma" and B.65 "Treatment of patients with acute lymphoblastic leukemia for UC" Part 1 1. The subject of the order is the delivery of the product medicinal product Brexucabtagene autoleucel for UCK in the assortment, estimated quantity and requirements specified in Annex 3 to the SWZ. 2. The Ordering Party does not allow the submission of partial offers. The subject of the order is one medicinal product. 3. Within items marked in the assortment and price form with the symbol (**) in Annex No. 3 to the SWZ, the Ordering Party requires that the offered preparation be included in the catalog of reimbursed drugs used in drug programs. 4. The Ordering Party requires the prices of medicines offered were no higher than the official prices specified in Art. 9 section 1 and 2 of the Act of May 12, 2011 on the reimbursement of medicines, foodstuffs intended for particular nutritional uses and medical devices (Journal of Laws of 2024, item 930), in force as of submitting offers. 5. The offered medicinal products must comply with the Act of September 6, 2001, Pharmaceutical Law (Journal of Laws of 2024, item 696) - if applicable. The offered medicinal products must be authorized for marketing in Poland principles specified in Art. 3 or 4a of the Pharmaceutical Law. 6. If the Ordering Party used standard designations, technical assessments in the description of the subject of the order...
Document Type: Contract Notice Reference Number: 207/PN/2026 Contract Type: supplies Authority Type: body-pl Doc Title: 207/PN/2026 - Delivery of the medicinal product Brexucabtagene autoleucel - annual demand for drug programs: B.12.FM "Treatment patients with B-cell lymphoma" and B.65 "Treatment of patients with acute lymphoblastic leukemia for UCK" Dispatch Date: 2026-07-13 Publish Date: 2026-07-14 Submission Date: 2026-08-13

Documents

 Tender Notice